Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADOIF
Adocia
C$8.87
C$8.87
C$8.87
▼
C$11.24
N/AN/A2,000 shsN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
$0.00
$0.00
▼
$0.01
N/A12251 shsN/A
Genfit S.A. stock logo
GNFTF
Genfit
$15.95
$11.90
$4.14
▼
$15.95
N/AN/A437 shs40 shs
TRSBF
3SBio
$2.12
$2.19
$2.00
▼
$4.74
N/AN/A2,351 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADOIF
Adocia
0.00%0.00%0.00%0.00%0.00%
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00%0.00%0.00%0.00%0.00%
Genfit S.A. stock logo
GNFTF
Genfit
0.00%0.00%+48.37%+68.43%+328.76%
TRSBF
3SBio
0.00%-1.48%-1.48%-25.68%-47.05%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADOIF
Adocia
C$8.87
C$8.87
C$8.87
▼
C$11.24
N/AN/A2,000 shsN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
$0.00
$0.00
▼
$0.01
N/A12251 shsN/A
Genfit S.A. stock logo
GNFTF
Genfit
$15.95
$11.90
$4.14
▼
$15.95
N/AN/A437 shs40 shs
TRSBF
3SBio
$2.12
$2.19
$2.00
▼
$4.74
N/AN/A2,351 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADOIF
Adocia
0.00%0.00%0.00%0.00%0.00%
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00%0.00%0.00%0.00%0.00%
Genfit S.A. stock logo
GNFTF
Genfit
0.00%0.00%+48.37%+68.43%+328.76%
TRSBF
3SBio
0.00%-1.48%-1.48%-25.68%-47.05%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADOIF
Adocia
0.00
N/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00
N/AN/AN/A
Genfit S.A. stock logo
GNFTF
Genfit
0.00
N/AN/AN/A
TRSBF
3SBio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADOIF
Adocia
N/AN/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/AN/A
Genfit S.A. stock logo
GNFTF
Genfit
N/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADOIF
Adocia
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/A-$0.84N/AN/AN/AN/AN/AN/AN/A
Genfit S.A. stock logo
GNFTF
Genfit
N/A-$0.67N/AN/AN/AN/AN/AN/A9/29/2026 (Estimated)
TRSBF
3SBio
N/AN/AN/AN/AN/AN/AN/AN/A8/26/2026 (Estimated)

Latest GNFTF, TRSBF, ATRX, and ADOIF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/26/2026N/A
TRSBF
3SBio
$0.0942N/AN/AN/A$689.32 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ADOIF
Adocia
N/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/A
Genfit S.A. stock logo
GNFTF
Genfit
N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ADOIF
Adocia
N/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/A
Genfit S.A. stock logo
GNFTF
Genfit
11.11%
TRSBF
3SBio
N/A

Insider Ownership

CompanyInsider Ownership
ADOIF
Adocia
N/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
28.20%
Genfit S.A. stock logo
GNFTF
Genfit
N/A
TRSBF
3SBio
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ADOIF
Adocia
97N/AN/ANot Optionable
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
211.63 million8.35 millionNot Optionable
Genfit S.A. stock logo
GNFTF
Genfit
159N/AN/ANot Optionable
TRSBF
3SBio
5,411N/AN/ANot Optionable

Recent News About These Companies

3SBio Board to Review 2026 Interim Results and Consider Dividend
August 7 at 7:31 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/3sbio-board-to-review-2026-interim-results-and-consider-dividend?utm_source=marketbeat.com&utm_medium=referral
3SBio Sets June 2026 AGM to Approve Dividend, New Auditor and Share Issue Mandate
June 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/3sbio-sets-june-2026-agm-to-approve-dividend-new-auditor-and-share-issue-mandate?utm_source=marketbeat.com&utm_medium=referral
3SBio Calls Extraordinary Meeting to Approve Mandi Spin-Off Dividend
April 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/3sbio-calls-extraordinary-meeting-to-approve-mandi-spin-off-dividend?utm_source=marketbeat.com&utm_medium=referral
3SBio Proposes HKD 0.25 Final Dividend for 2025 Financial Year
March 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/3sbio-proposes-hkd-0-25-final-dividend-for-2025-financial-year?utm_source=marketbeat.com&utm_medium=referral
Chinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- Update
May 20, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/chinese-biotech-stocks-surge-after-3sbio-s-6-billion-licensing-deal-with-pfizer-update-22768f03
Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer
May 20, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/biotech-company-3sbio-s-shares-surge-after-6-billion-licensing-deal-with-pfizer-6bf7cbed
Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion
May 20, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/pfizer-licenses-3sbio-cancer-drug-for-record-12-billion/ar-AA1F5ZDf
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
July 28, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cosmo-and-3sbio-announce-signing-of-license-agreement-for-winlevi-174-in-china-1031624145
3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development
August 26, 2021  |  finance.yahoo.comhttps://finance.yahoo.com/news/3sbio-announces-2021-interim-results-140900893.html?.tsrc=rss

New MarketBeat Followers Over Time

Adocia OTCMKTS:ADOIF

C$8.87 0.00 (0.00%)
As of 05/12/2023

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Adhera Therapeutics stock logo

Adhera Therapeutics OTCMKTS:ATRX

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Genfit stock logo

Genfit OTCMKTS:GNFTF

$15.95 0.00 (0.00%)
As of 08/7/2026

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

3SBio OTCMKTS:TRSBF

$2.12 0.00 (0.00%)
As of 08/7/2026

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas